Drugs.com - New Drug Approvals

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Ospomyv (denosumab-dssb; SB16; 60 mg pre-filled syringe)...

Feb 17, 2025 - 07:28
 0
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia
INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Ospomyv (denosumab-dssb; SB16; 60 mg pre-filled syringe)...
Read More

Tags:

Previous Article

Allergan Aesthetics Introduces New AMI Training Centers Across the US

Next Article

UAE expands Visa-on-Arrival for Indian Nationals

Related Posts

FDA Approves Simplified Dosing Regimen for Acetadote (N-acetylcysteine for injection)

FDA Approves Simplified Dosing Regimen for Acetadote (N...

Feb 9, 2025  0

ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions in Pediatric Patients

ARS Pharmaceuticals Announces FDA Approval of neffy 1 m...

Mar 6, 2025  0

FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

FDA Approves Zepbound (tirzepatide) as the First and On...

Feb 9, 2025  0